4 -2x10^8 cells) for treatment of blood cancers. The product is also approved by US FDA and Health Canada. Thus clinical trials

A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.

This study looks at a new cell therapy called C2C_ASC110 for people with a type of heart failure where the heart doesn't pump blood well. Researchers want to see if this therapy improves heart function compared to a dummy treatment over six months.